◆ NeutralHUMAHUMAW

Humacyte Appoints Key Nephrologists as Advisors to Prepare for Planned Commercialization of the ATEV in Dialysis Access

GlobeNewswire Inc.·
Humacyte Appoints Key Nephrologists as Advisors to Prepare for Planned Commercialization of the ATEV in Dialysis Access

Humacyte, Inc. announced the appointment of two prominent nephrologists, Dr. Robert J. Kossmann and Dr. Prabir Roy-Chaudhury, as advisors to support the commercialization of its acellular tissue engineered vessel (ATEV) for hemodialysis access. The appointments follow positive Phase 3 V012 study results in women and plans to file a supplemental Biologic License Application with the FDA.

Read Full Article at GlobeNewswire Inc.
← Back to Financial Intelligence